Cobimetinib - Wikipedia
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. [2] [8] Cobimetinib is a MEK inhibitor. [2] Cobimetinib is marketed by Genentech. [2]
Genentech: Cotellic® (cobimetinib) - Information for Patients
Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. This service offers coverage support, patient assistance, and other useful information. Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine.
Cobimetinib Uses, Side Effects & Warnings - Drugs.com
2022年12月14日 · Cobimetinib is used in adults to treat a certain type of metastatic melanoma (skin cancer) that has spread to other parts of the body and cannot be removed with surgery. Cobimetinib is usually given together with another medicine called vemurafenib.
Cobimetinib (oral route) - Mayo Clinic
2024年2月1日 · Cobimetinib is used in combination with vemurafenib to treat melanoma (skin cancer) that has spread or that cannot be removed by surgery. It is only used if the melanoma cells have the BRAF V600E or V600K mutations.
Cobimetinib: MedlinePlus Drug Information
Cobimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Cobimetinib: Uses, Interactions, Mechanism of Action - DrugBank …
Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.
Cobimetinib Fumarate - NCI - National Cancer Institute
Cobimetinib fumarate is approved to be used to treat: Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used with vemurafenib in patients whose cancer has a certain mutation in the BRAF gene. Histiocytic cancers. It is used alone in adults.
Cobimetinib: Dosage, Mechanism/Onset of Action, Half-Life
2020年2月10日 · Cobimetinib is a potent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway (Larkin 2014); it reversibly inhibits MEK1 and MEK2, which are upstream regulators of the extracellular signal-related kinase (ERK) pathway.
Cobimetinib Monograph for Professionals - Drugs.com
2024年3月10日 · Cobimetinib reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
Cotellic (cobimetinib) dosing, indications, interactions, adverse ...
Indicated as a single agent for adults with histiocytic neoplasms. 60 mg PO qDay for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. New primary...